News Updates
More Articles
- The Pitfalls and Promise of Cell and Gene Therapy Development: A Time for Concerted Action
- “Not Just Checking a Box”: A Call to Rethink Patient Involvement in the EU
- From Cells to Animals and Back Again: The Shifting Landscape of Cancer Efficacy and Safety Models
- Addressing Inequity: Embedding Inclusion and Diversity in UK Clinical Trials
- The Next AI Revolution: Computer System Validation
Changing Landscape of Evidence Charting New Assessment Pathways: Q&A with Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn
Global Forum discusses the concept of HTA and its place in the therapeutic development of pipeline products—first on a global basis and then within the context of Canadian and other international jurisdictions—with Suzanne McGurn, president and chief executive officer of the Canadian Agency for Drugs and Technologies in Health (CADTH).